16Apr/14

Cerilliant Introduces New Certified Snap-N-Spike® Solutions of Corticosteroids – Virtual Press Office (press release)

Cerilliant Introduces New Certified Snap-N-Spike® Solutions of Corticosteroids
Virtual Press Office (press release)
LOUIS, April 16, 2014 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that the Cerilliant® brand within its Applied Diagnostics and Testing Business Unit introduced four new Certified Spiking Solutions® of the corticosteroids …

and more »

11Apr/14

National Cancer Institute investigating trial outliers to resurrect 'failed' drugs – FierceBiotech

National Cancer Institute investigating trial outliers to resurrect ‘failed’ drugs
FierceBiotech
The patient, who had advanced bladder cancer, experienced a complete response for 14 months to the drug combination everolimus (Afinitor) and pazopanib (Votrient) in a Phase I trial. In the trial, investigators recruited 9 patients with advanced solid

and more »

10Apr/14

Abbott's Absorb Bioresorbable Scaffold Completes Enrollment in 3 Pivotal … – Angioplasty.Org


Angioplasty.Org
Abbott’s Absorb Bioresorbable Scaffold Completes Enrollment in 3 Pivotal
Angioplasty.Org
The trials pit the Absorb Bioresorbable Vascular Scaffold against Abbott’s flagship everolimus-eluting XIENCE stent in almost 3,000 patients worldwide. The Absorb BVS also elutes everolimus. One of the primary theoretical advantages of this device is
Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United Benzinga
Abbott Completes Enrollment of Absorb(TM) Randomized Clinical Trials in the Wall Street Journal

all 6 news articles »